SPINK1

(redirected from PSTI)
Also found in: Acronyms.

SPINK1

A gene on chromosome 5q32 that encodes a trypsin inhibitor secreted from pancreatic acinar cells into pancreatic juice. SPINK1 is thought to prevent trypsin-catalysed premature activation of zymogens within the pancreas and the pancreatic duct.

Molecular pathology
SPINK1 mutations are associated with hereditary pancreatitis and tropical calcific pancreatitis.
References in periodicals archive ?
Adapters and sequences PstI 5' ctc gta gac tgc gta cat gca cat ctg acg cat gt 5' EcoRI 5' ctc gta gac tgc gta cc cat ctg acg cat ggt taa 5' MseI 5' gac gat gag tcc tga gta ctc agg act cat 5' Primers and sequences PstI + a 5' gactgcgtacatgcag- aXX ([dagger]) EcoRI + a 5' gactgcgtaaccaattc- aYY ([double dagger]) MseI + c 5' gatgagtcctgagtaa- cZZ ([section]) ([dagger]) XX are null for plus 1 primers; CA, CC, or CT for plus 3 primers.
PstI and RsaI RFLPs in complete linkage disequilibrium at the CYP2E gene.
kit), 1.5 mM MgC12, 0.2 U Taq polymerase; 15 mL total volume] differed from the PstI:MseI SA PCR cocktail (2 mL 10x PCR buffer, 5 ng PstI+A-XX, 30 ng Mse+C-ZZ, 0.2 mM each dNTP, 1.5 mM MgC12, 0.2 U Taq polymerase; 15 mL total volume).
H PIC Xmnl (a) X1 0.8207 0.3853 0.3434 X2 0.1793 G [right arrow] A A 0.2119 0.3307 0.2713 G 0.7881 PstI P1 0.9348 0.1231 0.1160 P2 0.0652 SstI (a) S1 0.7554 0.3697 0.3006 S2 0.2446 HincII N 0.7119 0.4106 0.3266 S 0.2881 Hypertriglyceridemics RFLP sites Allele Freq.
iso- Anti- with the probe Strain lated biogram HindIII BglII PstI SG24 1992 CoFzS 23 8.0, 9.3, 7.0 5.6 AM258 1996 ACCfFzNS 14.0, 23.00 7.0, 9.2, 5.6 7.0 PG265 1998 AFz 18.0 8.0 5.6 PG269 1998 AFz 18.0 8.0 5.6 PG316 1998 AFz 18.0 8.0 5.6 PG337 1998 AFzNS 14.0, 23 7.0, 9.2, 5.6 7.0 PG351 1998 AFz 16.0 8.0 5.6
(MAB216) PHILIP PEAD - PER-SE TECHNOLOGIES INC (PSTI).
Food and Drug Administration (FDA) has granted fast track designation to Pluristem Therapeutics' (PSTI) ongoing Phase 3 study of PLX-PAD cells for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization.
(PSTI) said it has received positive feedback from the U.S.
Pluristem (NasdaqCM: PSTI)(TASE: PLTR), a biotechnology company, has signed a strategic partnership and licensing agreement with Cha Bio&Diostech, it was reported yesterday.
Tickers featured: CERN, CVS, DSCM, ECLP, HLTH, IDXC, MCK, MDLI, MDRX, NDC, PLRX, PSTI, RX, TZIX, WAG.
* Pluristem Therapeutics Inc.(NASDAQ: PSTI) rose 6.4% to close at $4.53.
(PSTI) announced the publication of a study featuring PLacental eXpanded (PLX) cells conducted by independent scientists at the Berlin-Brandenburg Center for Regenerative Therapy at Charite - University Medicine Berlin.